Cinctive Capital Management LP Grows Stock Holdings in Hologic, Inc. $HOLX

Cinctive Capital Management LP lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 53.4% in the third quarter, HoldingsChannel.com reports. The firm owned 66,404 shares of the medical equipment provider’s stock after purchasing an additional 23,119 shares during the period. Cinctive Capital Management LP’s holdings in Hologic were worth $4,482,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Hologic by 10.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares during the period. Empowered Funds LLC lifted its holdings in Hologic by 27.7% in the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after buying an additional 3,790 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Hologic in the 2nd quarter worth approximately $454,000. Allworth Financial LP grew its position in shares of Hologic by 120.3% in the 2nd quarter. Allworth Financial LP now owns 1,511 shares of the medical equipment provider’s stock worth $98,000 after buying an additional 825 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Hologic by 1.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after buying an additional 97,142 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HOLX. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research note on Friday, November 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Finally, Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Two analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, Hologic presently has an average rating of “Hold” and an average target price of $78.42.

Hologic Stock Down 0.1%

HOLX stock opened at $75.12 on Monday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The company has a market capitalization of $16.77 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. The business’s 50 day moving average price is $75.13 and its two-hundred day moving average price is $72.72. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the business earned $0.87 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.